The diagnostic accuracy of the age-adjusted and prostate volume-adjusted biopsy method in males with prostate specific antigen levels of 4.1-10.0 ng/mL

Cancer

Volumn 95, Issue 10, 2002, Pages 2112-2119

  Ito, Kazuto ^a,b   Ohi, Masaru ^a   Yamamoto, Takumi ^a   Miyamoto, Shigeto ^a   Kurokawa, Kohei ^a   Fukabori, Yoshitatsu ^a   Suzuki, Kazuhiro ^a   Yamanaka, Hidetoshi ^a  

^a GUNMA UNIVERSITY   (Japan)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Prostate biopsy; Prostate carcinoma; Prostate specific antigen; Transperineal; Transrectal

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ANTIGEN SPECIFICITY; ARTICLE; BIOPSY TECHNIQUE; CALCULATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

AGE FACTORS; AGED; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0037110623     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10941     Document Type: Article

References (34)

1. Keetch DW, Catalona W, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen levels. J Urol. 1994;151:1571-1574.
2. Borboroglu PG, Comer SW, Riffenburgh RH, Amling CL. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol. 2000;163:158-162.
3. Allen EA, Kahane H, Epstein JI. Repeat biopsy strategies for men with atypical diagnosis on initial prostate needle biopsy. Urology. 1998;52:803-807.
4. Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol. 1998;159:1247-1250.
5. Roehrborn CG, Pickens GJ, Sanders JS. Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathological diagnoses and prostate specific antigen levels. Urology. 1996;47:347-352.
6. Ellis WJ, Brawer MK. Repeat prostate needle biopsy: Who needs it¿ J Urol. 1995;153:1496-1498.
7. Djavan B, Zlotta AR, Ekane S, et al. Is one set of sextant biopsies enough to rule out prostate cancer? Influence of transition and total prostate volumes on prostate cancer yield. Eur Urol. 2000;38:218-224.
8. Epstein JI, Walsh PC, Akingba G, Carter HB. The significance of prior benign needle biopsies in men subsequently diagnosed with prostate cancer. J Urol. 1999;162:1649-1652.
9. Uzzo RG, Wei JT, Waldbaum RS, Perlmutter AP, Byrne JC, Vaughan ED Jr. The influence of prostate size on cancer detection. Urology. 1995;46:831-836.
10. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol. 1997;157:199-203.
11. Vashi AR, Wojno KJ, Gillespie B, Oesterling JE. A model for the number of cores per prostate biopsy based on patient age and prostate gland volume. J Urol. 1998;159:920-924.
12. Vis AN, Boerma MO, Ciatto S, Hoedemaeker RF, Schröder FH, Kwast TH. Detection of prostate cancer: A comparative study of the diagnostic efficiency of sextant transrectal versus sextant transperineal biopsy. Urology. 2000;56: 617-621.
13. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostatespecific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer. 1993;71:2031-2040.
14. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA. 1996;275:288- 294.
15. Bassler TJ Jr., Orozco R, Bassler IC, O'Dowd GJ, Stamey TA. Most prostate cancer missed by raising the upper limit of normal prostate-specific antigen for men in their sixties are clinically significant. Urology. 1998;52:1064-1069.
16. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. Cancer. 2000;50:7-33.
17. Ito K, Kubota Y, Banzai R, et al. The present status, problems, and future of mass screening for prostate cancer in Gunma prefecture - The report of mass screening for prostate cancer study meeting in 1998. Kitakanto Med J. 1999; 49:81-88.
18. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostate carcinoma with prostate specific antigen. J Urol. 1992;147:841-845.
19. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen based screening. JAMA. 1993;270:948- 954.
20. Mettlin C, Lee F, Drago J, Murphy GP. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer. 1991;67:2949-2958.
21. Labrie F, Dupont A, Suburu R, et al. Serum prostate specific antigen as prescreening test for prostate cancer. J Urol. 1992;147:846-852.
22. Ito K, Ichinose Y, Kubota Y, Imai K, Yamanaka H. Clinicopathological features of prostate cancer detected by transrectal ultrasonography-guided systematic six-sextant biopsy. Int J Urol. 1997;4:474-479.
23. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151: 1283-1290.
24. Babaian RJ, Toi A, Kamoi K, et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol. 2000;163:152-157.
25. Hummerer P, Huland H. Systematic sextant biopsies in 651 patients referred for prostate evaluation. J Urol. 1994;151: 99-102.
26. Levine MA, Ittman M, Melamed J, Lepor H. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol. 1998; 159:471-475.
27. Chang JJ, Shinohara K, Bhargava V, Presti JC Jr. Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. J Urol. 1998;160:2111-2114.
28. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet. 1986;11:60-63.
29. Orozco R, Kunnel B, O'Dowd GJ, Stamey TA. Positive prostate biopsy rate consistently increases with age at the same prostate- specific antigen level in patient with normal digital rectal examination. Urology. 1998;51:531-533.
30. Fowler JE Jr., Bigler SA, Kilambi NK, Land SA. Results of transition zone biopsy in black and white men suspected prostate cancer. Urology. 1999;53:346-350.
31. Keetch DW, Catalona WJ. Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values. J Urol. 1995; 154:1795-1797.
32. Bazinet M, Karakiewicz PI, Aprikian AG, et al. Value of systematic transition zone biopsies in early detection of prostate cancer. J Urol. 1996;155:605-606.
33. Fleshner NE, Fair WR. Indication for transition zone biopsy in detection of prostatic carcinoma. J Urol. 1997;157:556-558.
34. Chang JJ, Shinohara K, Hovey RM, Montgomery C, Presti JC Jr. Prospective evaluation of systematic sextant transition zone biopsies in large prostates for cancer detection. Urology. 1998;52:89-93.